A Pilot Feasibility Study of 99mTc EC DG SPECT/CT Imaging in the Treatment Response Evaluation in Patients With Locally Advanced Head and Neck Cancer
Interventional
Allocation: Non-Randomized, Endpoint Classification: Pharmacodynamics Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic
Persistent Disease within 6 months of CRT
6 months
No
Ezra Cohen, MD
Principal Investigator
University of Chicago
United States: Food and Drug Administration
11-0032
NCT01359267
April 2011
April 2014
Name | Location |
---|---|
University of Chicago | Chicago, Illinois 60637 |